Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.04
- Author:
Chunlu SHU
1
;
Daxing ZHU
2
;
Qinghua ZHOU
2
Author Information
1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation
Center, Chengdu 610041, China.
2. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Biomarkers;
Immune checkpoint inhibitor;
Lung neoplasms;
Neoadjuvant therapy
- MeSH:
Biomarkers;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Humans;
Immune Checkpoint Inhibitors;
Lung Neoplasms/drug therapy*;
Neoadjuvant Therapy
- From:
Chinese Journal of Lung Cancer
2022;25(2):130-136
- CountryChina
- Language:Chinese
-
Abstract:
Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downstage rates and pathological remission in the neoadjuvant setting. Predictive biomarkers are of great significance to identify the beneficiaries of neoadjuvant ICIs. At present, the biomarkers are still inconclusive. We summarized the clinical trials of neoadjuvant immune checkpoint inhibitors that have been disclosed so far, and reviewed the progress of the biomarkers associated with those trials.
.
